An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment.

The article discusses a clinical trial, NCT06675955, focusing on the impact of multiple sclerosis (MS) on physical function and the continued use of ocrelizumab. The study aims to evaluate the physical impact of MS from the participant's perspective, provide access to ocrelizumab, and assess its safety and tolerability. The trial is interventional, in phase 3, and involves administering ocrelizumab to participants previously enrolled in related studies. The recruitment status is not yet recruiting, with an enrollment target of 500 participants by December 31, 2029. [Extracted from the article]